BerGenBio to present at Biotech Showcase 2018
Bergen, Norway, 8 January 2018 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the Company will present a corporate update during the Biotech Showcase 2018 held at the Hilton San Francisco Union Square. The presentation will include a discussion of recent progress across BerGenBio’s phase II clinical trial programme with selective Axl inhibitor BGB324 (bemcentinib).Details of the presentation are as follows: · Date: January 9, 2018 · Time: 10:00 am PST · Room: